Results of Operations
Galileo has neither engaged in any operations nor generated any revenues to date and its only activities from inception to March 31, 2021 were organizational activities, those necessary to prepare for the initial public offering, described below, and identifying a target company for an initial business combination. Galileo does not expect to generate any operating revenues until after the completion of our initial business combination. Galileo generates non-operating income in the form of interest income on marketable securities held in the Trust Account. Galileo incurs expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses in connection with completing an initial business combination.
For the three months ended June 30, 2021, Galileo had a net loss of $12,312,374, which consists of operating costs of $1,399,263, change in fair value of promissory note of $850,000, change in fair value of warrant liabilities of $10,069,500, offset by interest income on marketable securities held in the Trust Account of $6,389.
For the six months ended June 30, 2021, Galileo had a net loss of $11,284,061, which consists of operating costs of $1,586,799, change in fair value of promissory note of $850,000, change in fair value of warrant liabilities of $8,877,600, offset by interest income on marketable securities held in the Trust Account of $30,338.
For the three months ended June 30, 2020, Galileo had a net loss of $1,301,788, which consists of operating costs of $75,232, change in fair value of warrant liabilities of $1,356,300, offset by interest income on marketable securities held in the Trust Account of $129,744.
For the six months ended June 30, 2020, Galileo had a net loss of $9,894, which consists of operating costs of $275,269, change in fair value of warrant liabilities of $;411,000, offset by interest income on marketable securities held in the Trust Account of $676,375.
For the year ended December 31, 2020, Galileo had a net loss of $1,531,192, which consisted of general and administrative costs of $795,613 and a change in the fair value of warrant liabilities of $1,479,600, offset by interest income on marketable securities held in the trust account of $744,021.
For the period from July 30, 2019 (inception) through December 31, 2019, Galileo had a net loss of $378,919, which consisted of interest income on marketable securities held in the trust account of $414,479 offset by general and administrative costs of $176,898 and a change in the fair value of warrant liabilities of $616,500.
For the year ended December 31, 2020, cash used in operating activities was $587,232. Net loss of $1,531,192 was reduced by interest earned on marketable securities held in the trust account of $744,021. A change in the fair value of warrant liabilities of $1,479,600 and changes in operating assets and liabilities provided $587,232 of cash for operating activities.
For the period from July 30, 2019 (inception) through December 31, 2019, cash used in operating activities was $231,770. Net loss of $378,919 was affected by interest earned on marketable securities held in the trust account of $414,479, a change in the fair value of warrant liabilities of $616,500, transaction costs allocable to warrant liabilities of $4,078, formation costs paid by the Sponsor of $5,000 and changes in operating assets and liabilities, which used $63,950 of cash from operating activities.
Liquidity and Capital Resources
On October 22, 2019, Galileo consummated its initial public offering of 13,800,000 units, which included the full exercise by the underwriters of the over-allotment option to purchase an additional 1,800,000 units, at $10.00 per unit, generating gross proceeds of $138,000,000. Simultaneously with the closing of the IPO, Galileo consummated the sale of 4,110,000 private warrants to the sponsor and EBC, at a price of $1.00 per private warrant, generating gross proceeds of $4,110,000.
Following the initial public offering, the exercise of the over-allotment option and the sale of the private warrants, a total of $138,000,000 was placed in the Trust Account. Galileo incurred $3,187,305 in transaction costs, including $2,760,000 of underwriting fees and $427,305 of other offering costs.
For the six months ended June 30, 2021, cash used in operating activities was $383,414. Net loss of $11,284,061 was affected by interest earned on marketable securities held in the Trust Account of $30,338, a change in the fair value of warrant liabilities of